Cold-cough

Commercial

Portfolio-7447-for-WEB

NCE Pipeline

Discovery-7447-for-WEB

Research

Latest Report and Accounts

Vernalis plc - AR 30-06-2016 - FINAL - COVER PAGE WEBSITE

30 June, 2016

2015/16 Results Download our latest report...

Archive

Latest Presentation

ceo01 December, 2016

Our latest presentation is available to view from here...


Archive

Share Price

Share price:  33.50p
Change:  0.75 (2.29%)
As at:  16 January 2017 12:23:25
Volume:  103,415
LSE ID:  VER

Share price details

Latest News

FDA accepts CCP-08 NDA for full review

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-08 New Drug Application ("NDA") for full review. This triggers a milestone payment from Vernalis to Tris. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch